How TrueMeds' Generic Medicine Model Saves Up to 80% in India

A generic medicine is a drug that contains the same active ingredient (salt), in the same dosage and strength, as the original branded medicine. It works in exactly the same way in your body. The key regulatory requirement in India is bioequivalence — meaning the generic must demonstrate it absorbs at the same rate and extent as the branded version, producing identical therapeutic outcomes.

So why does it cost so much less? The branded version of a medicine carries the R&D cost of discovering the molecule, running clinical trials, obtaining patents, and funding years of marketing campaigns to get doctors to prescribe it. Once the patent expires, any manufacturer that meets quality standards can produce the same molecule — without those enormous upfront costs. That saving flows directly to the patient.

In India, this dynamic has an important twist: most "branded" medicines are themselves branded generics — meaning the molecule was never truly patented in India. Companies like Cipla, Sun Pharma, and Dr. Reddy's sell branded versions of off-patent molecules. TrueMeds finds you an equivalent from the same pool of manufacturers, at a lower price point, from the top 1% of CDSCO-approved pharma companies in the country.

TrueMeds' core technology is a substitution algorithm that scans a database of over 2.5 lakh pharmaceutical products. When you upload a prescription or search for a medicine, the algorithm identifies alternatives that match on four parameters: active salt composition, dosage strength, route of administration (tablet, capsule, syrup), and therapeutic category. The goal is maximum savings while maintaining clinical equivalence.

What makes TrueMeds different from simply Googling a cheaper medicine is the mandatory medical consultation baked into every order. Before the order is confirmed, a doctor, pharmacist, or trained health advisor calls the patient to verify clinical appropriateness, explain the substitute, and address any questions. For chronic patients who've been on a specific brand for years, this human touchpoint matters enormously for trust and compliance.

The platform also includes automated refill reminders — a critical feature for chronic care. Skipping doses of blood pressure or diabetes medication can be genuinely dangerous, and TrueMeds' system tracks typical refill cycles and nudges patients before they run out. This isn't just a sales tool; it has a real impact on adherence and long-term health outcomes.

The savings vary significantly by medicine category. For common chronic-care molecules — metformin for diabetes, atorvastatin for cholesterol, amlodipine for blood pressure, and levothyroxine for thyroid — the gap between the most commonly prescribed branded version and a quality generic from the same molecule can be substantial. Below is an approximate comparison based on typical MRP ranges in India as of May 2026.

Multiplied across a full month's supply, and across 2–4 chronic medicines that many patients take simultaneously, the annual savings can run to several thousand rupees per household. In FY 2023–24, TrueMeds reported that its users collectively saved ₹132 crore by switching to substitute medicines — plus an additional ₹83 crore through app offers.

The economics of generic medicine savings compound over time. A patient who takes one medicine for a short illness for a week sees limited benefit. But a patient managing Type 2 diabetes, hypertension, or hypothyroidism — conditions requiring daily medication indefinitely — sees savings accumulate every single month for years. This is the segment TrueMeds has specifically targeted, and where the model delivers its most powerful impact.

In India, approximately 21% of the elderly population has at least one chronic disease. Over 77 million Indians have diabetes, and nearly 200 million have hypertension. Many of these patients are from Tier 2 and Tier 3 cities — exactly where TrueMeds reports 75%+ of its customer base lives. These are households where medicine affordability is not a convenience issue, it's a treatment adherence issue.

TrueMeds' model has particular relevance for elderly patients on fixed incomes, families where multiple members have chronic conditions, and households in smaller cities with limited access to discounted pharmacy chains. The pan-India delivery to 19,000+ pincodes means a patient in Gorakhpur or Bhavnagar can access the same medicine quality as someone in Mumbai.

The most common concern with switching to a generic medicine is: "Is it really as effective?" The regulatory answer is yes — provided the generic is CDSCO-approved and manufactured in a GMP-compliant (Good Manufacturing Practice) facility. CDSCO requires every approved generic medicine to demonstrate bioequivalence to the original — meaning it must show the same absorption rate, peak concentration, and therapeutic window.

TrueMeds takes this a step further by restricting its sourcing to the top 1% of pharmaceutical manufacturers in India. These are established companies that already supply medicines to branded players and export to regulated markets. Every medicine on the platform is CDSCO-approved, doctor-verified, and comes with pharmacist oversight during the consultation call.

One area to be aware of: for medicines with a narrow therapeutic index — such as anti-epileptics (phenytoin, valproate) or anti-coagulants (warfarin) — minor formulation differences can theoretically matter more. For these specific classes, always consult your doctor before switching. For the vast majority of chronic medicines — metformin, atorvastatin, amlodipine, levothyroxine, omeprazole — the switch is clinically well-supported.

India's online pharmacy market is crowded — 1mg, PharmEasy, Netmeds, and Apollo Pharmacy all offer home delivery with discounts. Where TrueMeds specifically differentiates is in its active substitution model. Most platforms let you order the medicine your doctor prescribed, sometimes with a small discount. TrueMeds' entire product is built around identifying a clinically equivalent but cheaper alternative — and providing medical backing for that switch.

The mandatory consultation call is a meaningful differentiator in a market where trust in generics remains low. 1mg and PharmEasy offer generics, but the patient typically has to identify and select a substitute themselves. TrueMeds' algorithm plus doctor call takes the research burden off the patient entirely. The company estimates an average 47% savings per order for users who switch brands.